Shimizu Hisako, Kawasaki Jun, Yuasa Shoji, Tarao Yoko, Kumagai Sachiyo, Kanemoto Kousuke
Utano National Hospital, Kansai Regional Epilepsy Center, Kyoto, Japan.
Seizure. 2003 Jul;12(5):282-6. doi: 10.1016/s1059-1311(02)00287-x.
Clobazam (CLB) add-on therapy was attempted in 183 patients with intractable complex partial seizures in whom conventional benzodiazepines had been successfully discontinued before initiation of CLB. Although complete remission was initially achieved in 61, tolerance developed in almost half (49.2%) within the first 3 months, whereas 23 out of 31 patients (74.2%) who remained seizure free for the first 3 months continued to be so over the next 3 months. CLB add-on therapy proved to be significantly more effective when concurrent GTC occurred more often than yearly. In the current series, no frank psychotic episodes were elicited among the 61 patients who achieved complete suppression of long-standing complex partial seizures, which was in agreement with previous studies. From these results, we believe that CLB is an effective, safe, and inexpensive medication for add-on therapy in difficult to treat focal epilepsies, especially without concurrent use of conventional benzodiazepine compounds.
对183例难治性复杂部分性癫痫患者尝试了氯巴占（CLB）附加疗法，这些患者在开始使用CLB之前已成功停用传统苯二氮䓬类药物。虽然最初有61例患者实现了完全缓解，但在最初3个月内几乎一半（49.2%）的患者出现了耐受性，而在最初3个月无癫痫发作的31例患者中有23例（74.2%）在接下来的3个月内继续保持无发作状态。当全身性强直阵挛发作（GTC）每年发作次数较多时，CLB附加疗法被证明明显更有效。在本系列研究中，在61例实现长期复杂部分性癫痫完全抑制的患者中未引发明显的精神病性发作，这与先前的研究一致。从这些结果来看，我们认为CLB是一种有效、安全且廉价的药物，用于难治性局灶性癫痫的附加治疗，尤其是在不联合使用传统苯二氮䓬类化合物的情况下。
